Drug Makers In India Move To Lifestyle Drugs For Income
This article was originally published in PharmAsia News
Executive Summary
Indian drug makers are reshaping portfolios in an effort to gain a greater share of lifestyle medicine sales. Among them is Alembic, whose emphasis has been on antibiotic and other acute-therapy drugs, but now moving into an emphasis on cancer, cardiovascular and diabetes drugs. Alembic acquired a non-oncology portfolio from Dabur Pharma last year to give it an entry into that market. Indian drug makers see lifestyle drugs as growing from the current 14 percent to 17 percent of the market by 2010. (Click here for more